Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) were down 1.5% during mid-day trading on Wednesday . The stock traded as low as C$22.04 and last traded at C$22.53. Approximately 2,033,666 shares traded hands during mid-day trading, an increase of 40% from the average daily volume of 1,451,591 shares. The stock had previously closed at C$22.20.
Several analysts have issued reports on VRX shares. TD Securities raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price target on the stock in a research note on Wednesday, November 8th. Royal Bank Of Canada reissued a “sector perform” rating and issued a C$23.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and a consensus price target of C$22.50.
In other news, Director Schutter Richard Urbain De purchased 10,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were purchased at an average price of C$14.33 per share, with a total value of C$143,300.00.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.